AUPHAurinia Pharmaceuticals Inc.
$16.65+28% 1Y
$16.65
$11.0552 weeks$18.62
The financials
Aurinia Pharmaceuticals Inc. by the numbers
Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $83M in Q2 2026 (quarter ended Jun 30, 2026), up 19% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $37M (45% of revenue). For the full year FY2025, revenue was $283M (+20% year on year) and net income $287M. Its largest product in Q2 2026 was License Collaboration And Royalty at $3.8M, 50.1% of the disclosed total, just ahead of Service at 49.9%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $83M | $70M | +19% |
| Gross profit | $77M | $63M | +22% |
| Operating income | $46M | $20M | +131% |
| Net income | $37M | $22M | +74% |
| Diluted EPS | $0.28 | $0.16 | +75% |
| Product | Revenue | Share |
|---|---|---|
| License Collaboration And Royalty | $3.8M | 50% |
| Service | $3.8M | 50% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $7.6M (-7.7%)
Service grew +12% year on yearLicense Collaboration And Royalty +11% year on year
Segment Latestquarter on quarteryear on year
- License Collaboration And Royalty$3.8M$3.8Mquarter on quarter -8.1%year on year +11%-8.1%+11%
- Service$3.8M$3.8Mquarter on quarter -7.3%year on year +12%-7.3%+12%